Home

Centerline Biomedical Appoints Jim Dillon President and Chief Executive Officer

via Business Wire

Centerline Biomedical, Inc. (“Centerline”), an innovative leader in cardiovascular navigation and visualization systems, announced the appointment of Jim Dillon as President and Chief Executive Officer (CEO) and a member of its board of directors. He will assume his responsibilities on August 18, 2025.

Mr. Dillon succeeds Gulam Khan, who has served as CEO since October 2022. Mr. Khan led Centerline Biomedical through a period of portfolio development. During his tenure, Centerline Biomedical developed, received 510(k) clearance, and commercialized its second-generation devices and appreciable software advances. We appreciate Gulam’s significant contributions.

“It is an honor to join Centerline at such a pivotal stage. The IOPS platform is poised for scaled growth and I am grateful to have the opportunity to lead the company as it continues to innovate such remarkable technology for patients and care givers,” said Mr. Dillon.

“With decades of med tech industry leadership, Jim brings deep cardiovascular sector experience leading portfolio innovation, operational alignment, and strategic financing for med tech companies,” said Todd Schwarzinger, Centerline’s Chairman. “Jim has a strong track record of driving commercial growth through category creation and market penetration and we are excited to have him leading Centerline.”

Mr. Dillon has previously served as President and CEO for cardiovascular innovation companies; BiVACOR, BioVentrix, Reprieve Cardiovascular and Renal Guard Solutions.

To learn more about the IOPS platform, visit www.centerlinebiomedical.com/iops-technology.

About Centerline Biomedical

Founded in 2015, Centerline Biomedical, Inc. is headquartered in Cleveland, Ohio. The company’s commercially available platform, IOPS® (Intra-Operative Positioning System), enables improved visualization and device navigation, while protecting patient and healthcare provider exposure from the harmful effects of fluoroscopic X-ray radiation during standard interventions. The company is a Cleveland Clinic Innovations spin-off investing in commercialization and development of technology to improve image guidance and reduce the need for fluoroscopic x-ray during transcatheter procedures. IOPS is indicated for use in the peripheral, aortic and aortic side branch vasculature. The IOPS platform consists of a mobile cart powered by proprietary visualization software and intelligent, sensorized IOPS catheters and guidewires.

Visit www.centerlinebiomedical.com for more information.

“It is an honor to join Centerline at such a pivotal stage. The IOPS platform is poised for scaled growth and I am grateful to have the opportunity to lead the company as it continues to innovate such remarkable technology for patients and care givers.”

Contacts